- Lobbying
- Lobbying by Cessation Therapeutics
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Anna karakitsos | Staff Assistant, Senate Environment and Public WorksCommittee (2008-2009), Research Assistant/Office Manager,Senate EPW Committee (2011-2012), Professional StaffMember, Senate EPW Committee (2012-2016) Staff Assistant, Senate Environment and Public Works Committee (2008-2009), Research Assistant/Office Manager, Senate EPW Committee (2011-2012), Professional Staff Member, Senate EPW Committee (2012-2016) |
Scott Segal | n/a |
Dylan Pasiuk | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Issues related to the fentanyl crisis and innovative treatment approaches..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate